CenTrial Logo

Linzagolix Shows Promise in Managing Endometriosis Pain


Clinical trial shows linzagolix provides new option for endometriosis pain relief

Endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus, often brings debilitating pain to affected women. However, research offers a new option in the form of linzagolix, a medication showing promising results in managing endometriosis-related pain.

Clinical Trial

In a comprehensive clinical trial called EDELWEISS 3, researchers investigated the effectiveness of linzagolix in alleviating endometriosis-associated pain. The trial involved 486 participants with moderate-to-severe pain, who were randomly assigned to different treatment groups.


The results revealed significant pain reduction in participants taking 200mg of linzagolix in combination with add-back therapy (ABT), compared to those receiving a placebo. Add-back therapy is a treatment approach used in combination with certain medications, like linzagolix, to help manage side effects while still providing effective treatment. This combination notably decreased both menstrual and non-menstrual pelvic pain over three months of treatment. Similarly, participants receiving a daily dose of 75mg of linzagolix also experienced a meaningful reduction in menstrual pain.

Linzagolix, particularly when combined with ABT, demonstrated better efficacy in managing endometriosis-associated pain compared to a placebo. Notably, the treatment improved the quality of life for participants and minimized the risks of bone loss and vasomotor symptoms commonly associated with hormonal treatments.


While the trial primarily focused on comparing linzagolix with a placebo, future research should explore its effectiveness in comparison to other standard treatments. Additionally, further investigation is needed to determine if linzagolix alone, at a lower dose of 75mg, can provide adequate pain relief without the need for additional hormonal therapy.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

These findings offer hope for individuals suffering from endometriosis-related pain, providing a potential alternative or adjunct to current treatment options. Linzagolix, particularly when combined with ABT, presents a promising avenue for managing pain and improving the quality of life for those with endometriosis.


The EDELWEISS 3 clinical trial highlights the potential of linzagolix as a valuable addition to the treatment arsenal against endometriosis-associated pain. While further research is needed to fully understand its long-term effects and comparative effectiveness, these initial findings bring optimism to individuals seeking relief from the burdensome symptoms of endometriosis.


Oxford Academic, Apr-22-24

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.